Top Markets
Coin of the day
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
주식 순위 #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
주가
$50.82
마지막 동기화: 2026-08-11
시가총액
$102.09M
변동 (1일)
1.90%
변동 (1년)
-
국가
US
거래 Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

카테고리

Hemab Therapeutics Holdings, Inc. Common Stock (COAG)의 주가 이력
최고 종가: $50.63 (2026-08-01 기준)

최저 종가: $27.02 (2026-05-01 기준)
Hemab Therapeutics Holdings, Inc. Common Stock의 주가 이력 (2026 ~ 2026)
연간 주가 성과
연도 성과
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH